Online citations, reference lists, and bibliographies.
← Back to Search

Epacadostat Plus Pembrolizumab In Patients With Advanced Melanoma And Select Solid Tumors: Updated Phase 1 Results From ECHO-202/KEYNOTE-037

Tara C. Gangadhar, O. Hamid, D. C. Smith, T. Bauer, J. Wasser, A. Olszanski, J. Luke, A. Balmanoukian, D. Kaufman, Y. Zhao, J. Maleski, M. Jones, L. Leopold, T. Gajewski
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share



This paper is referenced by
10.1007/978-3-662-58012-7_2
Melanom
L. Heinzerling (2019)
10.20517/2394-4722.2018.31
Immunotherapy in the treatment of colorectal cancer: a new kid on the block
A. Spallanzani (2018)
10.1016/j.critrevonc.2018.11.002
Advanced stage melanoma therapies: Detailing the present and exploring the future.
C. Luther (2019)
10.3389/fimmu.2018.01104
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
Paris Kosti (2018)
10.1016/S0140-6736(17)31601-X
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J. Schachter (2017)
10.1111/joim.12708
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
P. S. Chowdhury (2018)
10.1080/14656566.2019.1601700
Current and emerging systemic therapies for cutaneous metastatic melanoma
R. Mason (2019)
10.1097/PPO.0000000000000299
Clinical Development of PD-1 in Advanced Melanoma
R. Munhoz (2018)
10.1007/978-3-319-62431-0_17
IDO/TDO Inhibition in Cancer
G. Prendergast (2018)
10.1007/s11864-017-0458-0
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma
P. Ghatalia (2017)
10.1080/14712598.2017.1309388
Pembrolizumab use for the treatment of advanced melanoma
P. Specenier (2017)
10.1080/13543784.2019.1649657
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
A. I. Ingles Garces (2019)
10.2147/CMAR.S92546
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
Raghad M Abdul-Karim (2017)
10.1145/3403782.3403809
The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy
Z. Wang (2020)
10.1016/j.critrevonc.2018.07.001
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.
A. Stein (2018)
10.1007/s11912-019-0851-x
Novel Immunotherapy Combinations
Babar Bashir (2019)
10.5772/INTECHOPEN.73489
The Modern Approach to Targeting Melanoma
J. O'Sullivan (2018)
10.1080/14760584.2018.1506332
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
Julie M Collins (2018)
10.1080/13543784.2020.1793956
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials
Danilo Rocco (2020)
10.21037/cco.2017.06.14
Pancreas adenocarcinoma: novel therapeutics.
Benjamin A. Krantz (2017)
10.1097/PPO.0000000000000246
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
S. Hu-Lieskovan (2017)
10.3389/fonc.2018.00423
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
T. Komiya (2018)
10.1007/978-3-319-63757-0_8
Immune Checkpoint Combinations with Inflammatory Pathway Modulators
N. DeVito (2018)
10.1111/pcmr.12661
Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications
Grant M Fischer (2018)
10.1016/j.critrevonc.2017.09.007
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
I. Attili (2017)
10.3390/ijms20081903
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
B. Sacchetti (2019)
10.1016/j.trecan.2017.11.005
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
G. Prendergast (2018)
10.1039/c7mt00105c
Heme-containing enzymes and inhibitors for tryptophan metabolism.
Daojing Yan (2017)
10.1186/s40425-017-0285-7
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
D. Carvajal-Hausdorf (2017)
10.1016/j.bioorg.2019.103356
Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors.
Shi Cai (2019)
Report from the Canadian Melanoma Conference advances in immune therapy HigHLigHts
S. Ernst ()
10.1186/s13045-019-0730-9
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
D. Wang (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar